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Adult recipients of living donor liver transplantation (LDLT) have a higher incidence of biliary complications than recipients of
deceased donor liver transplantation (DDLT). Our objective was to define the intensity of the interventions and the time
to resolution after the diagnosis of biliary complications after liver transplantation. We analyzed the management and
resolution of posttransplant biliary complications and investigated the comparative effectiveness of interventions in LDLT and
DDLT recipients. For the analysis of biliary complications (leaks or strictures), we used a retrospective cohort of patients
who underwent liver transplantation at 8 centers between 1998 and 2006 (median follow-up from onset54.7 years). The
numbers, procedure types, and times to resolution were compared for LDLT and DDLT recipients. Posttransplant biliary com-
plications occurred in 47 of the 189 DDLT recipients (25%) and in 141 of the 356 LDLT recipients (40%). Biliary leaks consti-
tuted 38% of the post-DDLT biliary complications (n518) and 65% of the post-LDLT biliary complications (n591). The
median times to first biliary complications were similar for DDLT and LDLT (11 versus 14 days for leaks, P50.63; 69 versus
107 days for strictures, P50.34). Overall, 1225 diagnostic and therapeutic procedures, including reoperation and retrans-
plantation, were performed (6.565.4 per recipient; 5.563.6 for DDLT versus 6.865.8 for LDLT, P50.52). The median num-
ber of months to the resolution of a biliary complication (i.e., a tube-, stent-, and drain-free status) did not significantly differ
between the DDLT and LDLT groups for leaks (2.3 versus 1.3 months, P50.29) or strictures (4.9 versus 2.3 months,
P50.61). Although the incidence of biliary complications is higher after LDLT versus DDLT, the treatment requirements and
the time to resolution after the development of a biliary complication are similar for LDLT and DDLT recipients. Liver
Transpl 19:259–267, 2013. VC 2013 AASLD.
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The disparity between the numbers of available donor
organs and potential liver transplant recipients led to
the development of adult-to-adult living donor liver
transplantation (LDLT).1 As experience has accumu-
lated, it has become evident that biliary complications
constitute a large proportion of posttransplant recipi-
ent morbidity.2,3 Several factors have been identified
that may contribute to biliary leaks or strictures after
LDLT; these include the center volume, the number of
graft bile ducts, and the type of anastomosis per-
formed.4 Furthermore, although endoscopic therapies
can be successfully employed to treat the majority of
biliary problems in most recipients, LDLT recipients
may have less favorable responses.5
LDLT recipients have a higher overall incidence of
complications than recipients of deceased donor liver
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transplantation (DDLT). Despite the lower severity of
pretransplant disease, the hospitalization requirements
for medical and surgical complications are higher after
LDLT versus whole organ DDLT.6 Biliary complications
contribute importantly to the excess morbidity of this
procedure. Although most biliary complications do not
lead to graft loss or patient death, detailed analyses of
the management, treatment course, and resolution of
biliary complications after LDLT and DDLT across mul-
tiple dedicated transplant programs might contribute to
our understanding of the differences in and similarities
of biliary morbidities according to the allograft type. In
this study, we report on the comparative effectiveness
of the management of posttransplant biliary complica-
tions in LDLT and DDLT recipients who participated in




Data for this study were derived from the retrospective
cohort component of the A2ALL study from 8 of the
9 A2ALL centers. Data were collected via detailed
chart reviews and were supplemented with data from
the Scientific Registry of Transplant Recipients
obtained through a data use agreement. Seven hun-
dred twenty-six transplant candidates who had a
potential living donor and completed a history and
physical examination between January 1, 1998 and
February 28, 2003 were eligible for inclusion in the
study. Five hundred forty-five recipients who under-
went transplantation between May 1998 and May
2006 for nonfulminant indications were included in
the analysis (DDLT, 189; LDLT, 356). Recipients of
domino transplants were included in the DDLT group.
Information from the study database was supple-
mented by the abstraction of additional data (September
2010 to May 2011) on the course of treatment for all 188
recipients who experienced a biliary complication, which
was identified by the recording of a leak or stricture in a
patient’s chart. A bile leak was defined as a persistent
bilious drainage more than 7 days after surgery that was
identified by a radiological study or surgical exploration.
A biliary stricture was defined as a radiologically identi-
fied narrowing of the intrahepatic or extrahepatic bile
ducts occurring at any time after donation. Detailed se-
rial data on specific diagnostic and therapeutic interven-
tions related to biliary complications were collected;
these included hospitalizations, antibiotic courses, com-
puted tomography or ultrasound (CTUS), endoscopic ret-
rograde cholangiopancreatography (ERCP), magnetic
resonance cholangiopancreatography (MRCP), percuta-
neous transhepatic cholangiography (PTC), reoperation,
and retransplantation.
The study was approved by the institutional review
boards and privacy boards of the University of Michi-
gan Data Coordinating Center and each of the trans-
plant centers.
Statistical Methods
Study subjects were followed from the time of trans-
plantation to the earliest of retransplantation, death,
or biliary complication chart review. Descriptive statis-
tics are given as means and standard deviations for
continuous variables and as proportions for categorical
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variables. t tests were used to compare differences
between DDLT and LDLT for continuous characteris-
tics. Chi-square tests were used to compare differences
between DDLT and LDLT for categorical characteris-
tics. The numbers of procedures performed for DDLT
and LDLT recipients were compared with a t test after
a log transformation of the procedure counts.
The distributions for the numbers of procedures
performed per person overall and for each procedure
individually were compared graphically for DDLT
and LDLT recipients with box plots. The percentages
of outpatient procedures that were performed were
examined. A procedure was considered an outpatient
procedure if there was no corresponding hospitaliza-
tion record that included the date of the procedure.
We compared the percentages of procedures per-
formed on an outpatient basis for DDLT and LDLT
recipients with a logistic regression model to adjust
for a potential time trend. This model allowed us to
examine the association between the type of trans-
plant (DDLT versus LDLT) and the probability of a
procedure being performed on an outpatient basis
while we adjusted for the year of transplantation.
To study the time to the resolution of biliary compli-
cations, the time from the placement of a biliary tube,
stent, or drain until the removal of all tubes, stents,
and drains was examined with survival models. The
follow-up for this analysis started at the time of the
initial placement of the tube, stent, or drain and con-
tinued until the earliest of the following: the patient
became tube-, stent-, and drain-free; the patient
underwent retransplantation; the patient died; or the
study ended. The earliest date by which all tubes,
stents, and drains had been removed was considered
the time of resolution (event). Follow-up was censored
at retransplant, death, and the end of the study. The
time from the onset to the resolution of biliary compli-
cations was examined with Kaplan-Meier survival
curves by the transplant type (DDLT versus LDLT)
and by the complication type (leak and/or stricture).
Differences between DDLT and LDLT recipients were
compared for each type of complication with log-rank
tests. Potential factors associated with resolution were
tested via the fitting of multivariate Cox proportional
hazards regression models stratified by the complica-
tion type. Time-dependent Cox regression models
were used to examine the effects of developing a bili-
ary complication on long-term graft and patient out-
comes. Each of the variables in Table 1 was tested in
the survival models, and the best subset selection
method was used to look for a parsimonious model.
The rates of procedures performed by the months
since transplantation were compared for DDLT and
LDLT recipients. The rates were calculated as the num-
ber of procedures performed during a month divided by
the number of patients in the risk set during that
month. To test factors that might be associated with the
number of procedures performed per unit of time, nega-
tive binomial regression models were fit to the data.
Because the rate of procedures decreased rapidly soon
after transplantation and changed very little after
approximately 2 years, 2 separate models were fit. The
first model was fit for the first 2 years after transplanta-
tion and included a quadratic term for time. The second
model was fit for the time beyond 2 years after trans-
plantation and modeled time as a linear term.
All analyses were performed with SAS 9.2 (SAS
Publishing, SAS Institute, Inc., Cary, NC).
RESULTS
Patient Characteristics and Nature of Biliary
Complications
Forty-seven of the 189 DDLT recipients (25%) suffered a
biliary complication during the follow-up period, and
141 of the 356 LDLT recipients (40%) had a posttrans-
plant biliary complication. The baseline characteristics
are shown in Table 1. LDLT recipients had significantly
lower Model for End-Stage Liver Disease (MELD) scores
(P<0.001) in comparison with the DDLT group. The
number of biliary anastomoses was significantly higher
in the LDLT group (P<0.001), and so was the proportion
of patients undergoing complete Roux-en-Y reconstruc-
tion (P<0.001). Although the cold ischemia time was
shorter in the LDLT group (P<0.001), the duration of the
recipient operation was significantly longer (P<0.001).
Overall, a higher percentage of LDLT patients had a
biliary complication (40% versus 25%, P<0.001; Table
2). Among those with biliary complications, biliary
leaks predominated in the LDLT group (64.5% versus
38.3%, P50.005). However, the median times from
transplantation to the onset of a biliary leak were not
different for the 2 groups (11 days for DDLT and 14
days for LDLT, P50.63). Conversely, biliary strictures
were the predominant type of biliary complication in
the DDLT group (59.6% versus 32.6%). Again, the me-
dian times to onset were not significantly different (69
days for DDLT and 107 days for LDLT, P50.34).
Although the risk of any biliary complication was
higher after LDLT, the risk of strictures did not differ
(14.8% after DDLT and 12.9% after LDLT, P50.54).
Five subjects had a simultaneous biliary leak and
stricture (DDLT, 1; LDLT, 4).
Procedures for Biliary Complications
Overall, 1225 diagnostic and therapeutic procedures
were performed for the management of biliary complica-
tions. The proportions of procedures performed exclu-
sively for diagnostic purposes (without therapeutic
interventions) were similar in the DDLT and LDLT
groups [90/258 (34.9%) and 368/599 (38.1%), respec-
tively, P50.35]. The overall number of procedures per-
formed per patient, including diagnostic imaging,
therapeutic interventions, reoperation, and retransplan-
tation, was 5.563.6 for DDLT recipients and 6.865.8
for LDLT recipients (P50.52; Fig. 1). There were signifi-
cantly more PTC procedures performed per patient in
the LDLT group (P50.004), and there were significantly
more ERCP procedures performed per patient in the
DDLT group (P<0.001). Figure 2 shows that the propor-
tions of diagnostic and therapeutic procedures
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performed in an outpatient setting increased dramati-
cally over time (P<0.001). Across the entire study pe-
riod, the proportion of outpatient procedures was
significantly higher in the LDLT group (P<0.001).
Probability of Resolution After a Biliary
Complication
The cumulative probability of the resolution of biliary
complications (i.e., the definitive removal of a percuta-
neously or operatively placed tube, stent, or drain or
retransplantation) is shown in Fig. 3. In this analysis,
the time to resolution was initialized on the day on
which the biliary complication was diagnosed and/or
first treated. Within 6 months of diagnosis, the major-
ity of the biliary leaks (79% for DDLT and 92% for
LDLT) were resolved, and by 24 months, all had been
resolved. In comparison with biliary leaks, the proba-
bility of resolution for biliary strictures was lower for
recipients of both transplant groups. Nevertheless, 24
months after diagnosis, 95% of DDLT recipients with
biliary strictures and 94% of LDLT recipients with bil-
iary strictures were tube-, stent-, and drain-free.
The median time to a tube-, stent-, and drain-free
status after a biliary leak was 1 month longer for
DDLT recipients (2.3 months) versus LDLT recipients
TABLE 1. Characteristics of Recipients With Biliary Complications
DDLT (n547) LDLT (n5141) P Value*
Recipient age at transplant (years)† 49.4610.3 49.5610.0 0.95
Recipient sex [n (%)] 0.67
Male 30 (63.8) 85 (60.3)
Female 17 (36.2) 56 (39.7)
Recipient race [n (%)] 0.39
White 39 (83.0) 124 (87.9)
Nonwhite 8 (17.0) 17 (12.1)
Recipient body mass index (kg/m2)† 27.164.9 26.365.5 0.37
Diagnosis [n (%)]‡
HCV 18 (38.3) 63 (44.7) 0.44
Hepatocellular carcinoma 10 (21.3) 20 (14.2) 0.25
Alcohol 7 (14.9) 19 (13.5) 0.81
Cholestatic liver disease 8 (17.0) 31 (22.0) 0.47
Noncholestatic cirrhosis other than HCV or alcohol 14 (29.8) 33 (23.4) 0.38
Other 7 (14.9) 13 (9.2) 0.79
MELD score at transplant† 22.069.5 15.466.3 <0.001
Donor age (years)† 37.5613.4 37.169.9 0.83
Donor type [n (%)]
Donation after brain death 45 (95.7) Not applicable
Donation after cardiac death 2 (4.3) Not applicable
Bile ducts from donor graft [n (%)] <0.001
Missing 6 (4.3)
1 47 (100) 65 (46.1)
2 56 (39.7)
>2 14 (9.9)
Biliary anastomoses [n (%)] <0.001
Missing 12 (25.5)
1 35 (74.5) 88 (62.4)
2 45 (31.9)
3 8 (5.7)
Biliary anastomosis type [n (%)] <0.001
Missing 12 (25.5)
Not all Roux 28 (59.6) 78 (55.3)
All Roux 7 (14.9) 63 (44.7)
Cold ischemia time (minutes)† 446.46167.7 93.7699.1 <0.001
Duration of recipient operation (minutes)† 386.06119.1 533.56129.9 <0.001
Era of transplantation [n (%)] 0.08
1998-1999 6 (12.8) 23 (16.3)
2000-2001 19 (40.4) 76 (53.9)
2002-2003 21 (44.7) 42 (29.8)
2004-2006 1 (2.1)
*The P values were derived from 2-sample t tests for continuous characteristics and from chi-square tests for categorical
characteristics.
†The data are presented as means and standard deviations.
‡Multiple diagnoses were possible.
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(1.3 months); there was a 75% probability of resolu-
tion after 4.7 and 2.7 months for DDLT and LDLT
recipients, respectively (log-rank P50.29). After the
development of a biliary stricture, the median time to
a tube-, stent-, and drain-free status was 4.9 months
for the DDLT group and 2.3 months for the LDLT
group; there was a 75% probability of resolution after
6.6 months for DDLT recipients and 5.0 months for
LDLT recipients (log-rank P50.61). Among LDLT
recipients, the median time to biliary leak resolution
was not significantly different for those without a
Roux-en-Y anastomosis (1.5 months) and those with a
Roux-en-Y anastomosis (1.2 months).
When they were tested with multivariate Cox models
stratified by the complication type (leak/stricture),
none of the factors, including LDLT [hazard ratio
(HR)51.2, P50.37], had a significant influence on the
time to being tube-, stent-, and drain-free. When
LDLT was analyzed exclusively, the overall number of
biliary complication cases per center influenced the
time to being tube-, stent-, and drain-free. Experience
with more than 15 biliary complications at a center
was associated with a significantly shorter time to re-
solution (HR51.68, P50.04).
The rate of biliary-related procedures declined rap-
idly during the first 24 months after transplantation
and then remained relatively constant in both the
DDLT and LDLT groups (Fig. 4). The rates never fell
to zero, even 10 years after transplantation. During
the first 24 months, the procedure rates for DDLT
and LDLT recipients were similar, whereas an older
recipient age, a higher recipient body mass index, and
a recipient diagnosis of hepatitis C virus (HCV) were
associated with a higher rate of procedures in all
patients (Table 3). More than 24 months after trans-
plantation, the procedure rates were higher for LDLT
recipients versus DDLT recipients, but not to the
point of statistical significance by conventional
standards (P50.06). The rate of procedures was sig-
nificantly higher for recipients who had at least 1
Roux-type biliary anastomosis (risk ratio52.97,
P50.02) or whose initial biliary complication was a
stricture or a simultaneous leak and stricture (risk
ratio52.90, P50.02).
TABLE 2. Types of Initial Biliary Complications and





No complication [n (%)] 142 (75.1) 215 (60.4)
Complication type [n (%)] 47 (24.9) 141 (39.6)
Leak [n/N (%)] 18/47 (38.3) 91/141 (64.5)
Stricture [n/N (%)] 28/47 (59.6) 46/141 (32.6)
Both [n/N (%)] 1/47 (2.1) 4/141 (2.8)
Time to onset (days)†
Leak 11 (3-39) 14 (6-24)
Stricture 69 (32-217) 107 (55-278)
Both 80 (80-80) 19 (18-42)
*Chi-square tests were used for the proportions of each
type of complication among recipients with biliary compli-
cations (P50.005 for DDLT versus LDLT).
†According to t tests, there were no significant differences
in the mean time to onset for any of the complication
types between DDLT and LDLT. The data are presented
as medians (with first and third quartiles in parentheses).
Figure 1. Number of procedures performed per patient to diagnose and/or treat biliary complications.
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Association of Biliary Complications With
Subsequent Graft Failure and Death
In the absence of biliary complications, the risk
of graft failure was not significantly different for
LDLT recipients versus DDLT recipients (HR51.26,
P50.25). Once a biliary complication occurred, the
risk of subsequent graft loss, adjusted for recipient
age and diagnosis, donor age, and packed red blood
cell use, increased (HR for DDLT52.78, P<0.001; HR
for LDLT51.41, P50.06). After a biliary complication,
the rate of graft failure or death among DDLT recipi-
ents was approximately twice the rate among LDLT
recipients (HR for graft failure51.98, P50.04; HR for
mortality51.99, P50.05). However, when LDLT cut-
surface leaks were excluded from the analysis, the
rates of graft failure and death were no longer signifi-
cantly different for LDLT and DDLT recipients (HR for
Figure 2. Procedures performed on an outpatient basis by year. The actual values were calculated by the calendar year; the pre-
dicted percentages are based on a logistic regression model.
Figure 3. Probability of becoming tube-, stent-, and drain-free after the initial placement by the type of biliary complication and
the type of transplant.
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graft failure51.75, P50.10; HR for mortality51.69,
P50.15). All patients in this cohort who developed a
biliary leak were at increased risk of developing a sub-
sequent stricture (HR51.79, P50.01).
DISCUSSION
Biliary complications are the major cause of morbidity
following LDLT.7 Although these complications can be
intractable and potentially fatal, the incidence varies
widely among transplant centers.8,9 The overall inci-
dence of biliary complications ranges from 5% to 40%,
and they are associated with aberrant donor anatomy
and biliary ischemia.10,11 At present, most biliary
complications are diagnosed and treated with nonop-
erative techniques.8 Several studies have retrospec-
tively analyzed the long-term complete resolution of
biliary leaks and/or strictures after therapeutic inter-
ventions.5,12-14 However, the cumulative morbidity to
the recipient in the form of the total number of proce-
dures (invasive and noninvasive) and the time from
the onset of the complication to its resolution have
not been well documented. Most studies to date have
evaluated the clinical efficacy of a specific procedure
type and have not quantified all procedures required
per patient as a result of a biliary complication. In
TABLE 3. Models of Rates of Biliary Complication Procedures per Month
Estimate Risk Ratio P Value
Rates within first 2 years after transplantation
Time since transplantation (per month) 20.28 0.76 <0.001
Time since transplantation (per month2) 0.01 1.01 <0.001
LDLT (with DDLT as reference) 0.19 1.21 0.15
Stricture or stricture plus leak as initial biliary complication (with
leak only as reference)
0.26 1.30 0.045
Recipient age (per 10-year increase) 0.13 1.14 0.045
Recipient body mass index (per unit increase) 0.02 1.02 0.01
Recipient diagnosis of HCV 0.28 1.33 0.03
Rates more than 2 years after transplantation
Time since transplantation (per month) 20.02 0.98 0.02
LDLT (with DDLT as reference) 1.05 2.85 0.06
Stricture or stricture plus leak as initial biliary complication (with
leak only as reference)
1.07 2.90 0.02
At least 1 Roux-type biliary anastomosis (with no Roux type as reference) 1.09 2.97 0.02
NOTE: The following variables were tested in the models but were not statistically significant: recipient sex and race, MELD
score, medical condition at transplant, encephalopathy, ascites, donor age, and number of arterial anastomoses.
Figure 4. Rate of procedures by the time since transplantation.
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this study, we sought to document the pathway to the
resolution of biliary complications and to quantify the
related procedures in LDLT and DDLT recipients.
Percutaneous strategies can be used to repeatedly
dilate strictures, place and remove biliary stents, per-
form sphincterotomy, and update ductal imaging.
Unfortunately, the cumulative morbidity to the recipi-
ent is generally not studied in a comparative timeline
based on the graft type with anatomic and clinical
management details used to provide a comparison of
disability and/or human cost. Shah et al.15 recently
reported a series of 41 LDLT recipients who had bili-
ary complications. They noted that all but 4 patients
with strictures were managed with nonoperative inter-
ventions and that 96% were free of any biliary compli-
cations at the time of publication. However, 13 of 19
patients with a bile leak required reoperation. A simi-
lar study reported the outcomes of 1062 recipients,
including 106 LDLT recipients; 224 developed a bili-
ary complication treated by ERCP.5 During the 10-
year study period, more than 700 ERCP procedures
were performed, with definitive success achieved in
only 64% of the cases. Patients who received an LDLT
graft or had both a leak and a stricture were less
likely to respond to endoscopic therapy. Finally, a
recent review from Korea reported that the success
rate of endoscopic treatment for biliary strictures after
LDLT ranged from 37% to 71%.14
We believe that the current study is the first to
quantify the cumulative morbidity of biliary complica-
tions following LDLT in terms of the diagnostic and
therapeutic procedures performed and the time to the
resolution of complications. In the A2ALL cohort,
the incidence of biliary complications was higher in
the LDLT group. However, the average numbers of
procedures performed per patient were similar for
DDLT and LDLT recipients, and so were the average
times from transplantation to complications and the
times from the onset of complications to their resolu-
tion. The majority of biliary complications in all recipi-
ents were resolved within 6 months. However, 2 LDLT
recipients had persistent unresolved biliary leaks after
24 months of treatment, and 1 DDLT recipient had an
unresolved stricture after 2 years.
In this cohort, the incidence of biliary complications
was higher in the LDLT group. Biliary strictures were
the predominant manifestations of biliary complica-
tions in the DDLT group. Conversely, among LDLT
recipients, nearly two-thirds of the complications were
combinations of cut-surface bile leaks, which are a
unique feature of the LDLT procedure, and anasto-
motic bile leaks. In DDLT and LDLT recipients, the
occurrence of biliary leaks was associated with a sig-
nificantly increased risk of subsequent strictures.
It is not surprising that the majority of invasive and
noninvasive procedures were performed in the first 2
years after transplantation. In fact, this study
revealed a learning curve of biliary complication man-
agement as increased experience was directly associ-
ated with a shorter time to resolution. Although there
was a marked decline in the monthly rate of proce-
dures after 24 months, it is important to note that it
was not zero. Several LDLT and DDLT patients
continued to require interventions for biliary compli-
cations up to 10 years after transplantation. As
experience has accumulated over time, the rate of
procedures performed to treat these complications on
an outpatient basis has dramatically increased for
both LDLT and DDLT.
We have identified several factors associated with a
significantly higher rate of procedures in the first 2
years, including an older recipient age, a higher body
mass index, and a primary diagnosis of HCV. How-
ever, the donor source (DDLT versus LDLT) was not
significantly associated with procedure rates in this
model. The occurrence of a biliary complication per se
was associated with a higher risk of graft loss in both
groups. This effect was greater in DDLT recipients
when all biliary complications were considered, but it
was not statistically significant when cut-edge leaks
(which occur in LDLT but not with whole organ DDLT
grafts) were excluded from the analysis.
Although these data were derived from 8 large
transplant centers across North America via detailed
chart reviews at each center, as well as the Scientific
Registry of Transplant Recipients database, we
acknowledge several limitations. The current data set
is derived from a retrospective component of the
A2ALL study and is of moderate size. During the 13-
year study period, clinical practice patterns may have
changed with respect to the ways in which these diffi-
cult problems are treated. Furthermore, the diagnos-
tic/therapeutic approach to a specific problem, as
well as the surgical techniques employed, may vary
across centers. These differences may have influenced
our results, but they are difficult to study.
Biliary complications are a formidable problem in
liver transplantation, and their incidence is higher af-
ter LDLT. However, once a complication has occurred,
we have shown that the number of required interven-
tions and the time to complete resolution are similar
for LDLT and DDLT recipients. These findings high-
light the ongoing challenges of biliary complications
after liver transplantation regardless of the donor
source. Overall, these data refute the common impres-
sion that biliary complications are a more protracted
problem and are less likely to be resolved after LDLT
versus DDLT.
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